Device for electrotherapy

 

The proposed device relates to medical equipment, namely, devices for electrotherapy. The technical result is to increase the safety of the patient during the procedure of electrotherapy by limiting current density under the electrodes to secure for the patient level. The device includes electrodes, connected in series shaper signal exposure and level control of the driving amplitude, connected in series limiters current density impact on the number of electrodes and multi-pin connectors of the connection electrodes connected between the control level of the driving amplitude and the electrodes. Each of the electrodes is connected to its output limiter current density impact through the first contact of his multi-pin connector. The other contacts of the connector-side electrodes supplied with jumpers for different values of the electrode area. On the other hand, the contacts are connected to the inputs of its limiting current density effects. 2 Il.

The proposed device relates to medical equipment, namely, devices for electric is ocedur, for example in physiotherapy.

The regulation of the procedure of electrotherapy [1] provides for the imposition of replaceable electrodes of different shapes and areas on the skin of the patient through the wet pads, providing a reliable contact of the electrode with the patient's body and eliminating the possibility of damage to the skin of the patient due to gapping to him electrode and locally exceeding the maximum permissible current density. The amount of current through the electrodes is established by the medical staff according to subjective feelings of the patient at the beginning of the session electrotherapy, the change in output voltage (current) devices for electrotherapy, the output of which is connected to the electrodes placed on the patient's body.

When the medical staff with a device for electrotherapy possible errors associated with the replacement of the electrodes. For example, if at a constant setting device (the current value of the patient) to replace one electrode to another, having a smaller area, it is possible to exceed the maximum allowable current density of 0.1 mA/cm [1], causing the patient a feeling of burning or postrelease during the procedure and causing burns to the skin surface of the patient under the electrodes. Similar to the program session during uncontrolled increase in the intensity of the impact (current through the electrodes, superimposed on the patient's body).

Known devices for electrotherapy [2-4] for the impact on the affected organs of the patient by currents of different forms through the electrodes for the purpose of their treatment, prevention, training and strengthening. A common feature of the known devices is the presence in their structure of the actual device for electrotherapy and a set of replaceable electrodes with cables lead. Replaceable electrodes have different area and connect its cables lead supplied with the bit connectors to the corresponding connectors of the device.

The closest in terms of total signs is the electrostimulator [5], containing connected in series shaper signal impacts the level control of the driving amplitude and the electrodes.

This device (prototype) does not ensure patient safety during the procedure, as with the errors of the medical staff when setting the intensity of the exposure and when faulty operation of the shaper signal influence or control the amplitude level of the impact.

The aim of the invention is to increase the safety of the patient during the procedure of electrotherapy by limiting deposada.

To achieve this goal in the device selected as a prototype, inputs connected in series limiters current density impact on the number of electrodes and multi-pin connectors of the connection electrodes connected between the control level of the driving amplitude and the electrodes, each electrode connected to the output of its limiter current density impact through the first contact of his multi-pin connector, the other contacts of the connector-side electrodes supplied with jumpers for different values of the electrode area, and on the other hand are connected with the inputs of its limiting current density effects.

Thus, the combination of the above features allows you to meet the goal of improving the safety of the patient during the procedure of electrotherapy by limiting the allowable current density under the electrode to secure for the patient level in any area of the connected electrode, as with the errors of the medical staff when setting the intensity of the exposure and when faulty operation of the shaper signal influence or control the amplitude level of the impact.

In Fig.1 pred of serially connected signal shaper impact 2, level control of the driving amplitude of 3 and a set of constraints of the current density impact 4-5, United inputs each with its level control amplitude effects 3, and outputs (a) each first contact (a) its multi-position connector 6-7. Other contacts (b-e) multi-pin connectors 6-7 are connected respectively with the same inputs (b-e) its limiting current density impact 4-5. The structure of the device also includes a set of interchangeable electrodes of various sizes 8-9, each of which is through your cable lead 10-11 connected to the first contact of (a) its multi-position connector 12-13. The area of the electrodes 8-9 is encoded by a set of jumpers installed between pin b and the contacts C, d, e multipole connectors 6-7, respectively. For example, for the electrode 8 having a minimum area, the jumper on the connector 6 is installed only between contacts b and C, and the electrode 9 having the maximum area, the jumper on the connector 7 is installed between pins b and C, b and d, b and e.

In Fig.2 shows a variant implementation of an electrical circuit limiting current density impact 4-5.

The limiter current density impact sodered 16 is connected to the collector of the first n-p-n transistor 17 and one of the terminals of the resistor 18, the other output of which is connected to the base of the first n-p-n transistor 17 and the collector of the second n-p-n transistor 19, the base of which is connected to the emitter of the first n-p-n transistor 17 and one of the conclusions of each of the resistors 20, 21, 22, other terminals of the resistors 20, 21, 22 each connected with its anode of diode 23, 24, 25. The cathodes of diodes 23, 24, 25 are connected respectively to the outputs of the letters C, d, e. The emitter of the second n-p-n transistor 19 is connected to the anode of diode 26 and the cathode of diode 26 with outputs, denoted by the letters a and b.

The input 14 is also connected to the channel limitations flowing from electrode of the patient's current 27 to the cathode of the diode 28. The anode of diode 28 is connected to the collector of the first p-n-p transistor 29 and one pin of the resistor 30, the other output of which is connected to the base of the first p-n-p transistor 29 and the collector of the second p-n-p transistor 31, the base of which is connected to the emitter of the first p-n-p transistor 29 and one of the conclusions of each of the resistors 32, 33, 34, other terminals of the resistors 32, 33, 34 each connected with its cathode of diode 35, 36, 37. The anodes of the diodes 35, 36, 37 are connected respectively to the outputs of the letters C, d, e. The emitter of the second p-n-p transistor 31 is connected to the cathode of the diode 38 and the anode of diode 38 with outputs, denoted by the letters a and b.

Deov both channels, connected to the same outputs, indicated by the letters C, d, e, must be equal, i.e.,

Let the limiter current density impact connected electrode 8 having a minimum area of Sminthat corresponds to the jumper shown in the diagram of Fig.2 by the dotted line.

The resistor 20 R20is calculated by the formula (2)

where UEB- saturation voltage base-emitter voltage of the second transistor 19;

Imax(Sminmaximum allowable current for the electrode 8 having a minimum area of Smin; calculated by the formula (3)

where Ismax- the maximum current density under the electrode equal to 0.1 mA/cm2[1].

Asking a job step the electrode area equal to Sminselected R21=R20/2 and R22=R20/4.

With jumpers between pin b and the three contacts C, d, and E. the multi-connector cable leads of each of the electrodes may encode its area (and accordingly, the current limit for this area) in the range from Sminto Smax=7·Sminwith a step equal to the of Osada electrodes Smax/Sminyou should increase the number of contacts the multi-connector cable leads of each of the electrodes that are used to encode the electrode area.

Device for electrotherapy works as follows. The voltage from the signal shaper impact 2 is fed to the input level control of the driving amplitude 3, where the staff sets the level of the amplitude of current or voltage coming forth with its outputs through limiting current density impact 4-5 and, accordingly, the contacts (a) pairs of multi-pin connectors 6, 12-7, 13 through the cable lead 10-11 on the electrodes 8-9.

If due to medical error or due to a malfunction of the signal shaper impact 2 or level control of the driving amplitude 3, the level of amplitude of the resulting current in the circuit electrode 8 having a smaller area at the input of the limiter current density impact 4 exceeds the maximum value of Imax(Smin), the voltage drop across the resistor 20 is applied to the base - emitter voltage of the second n-p-n transistor 19, opens and enters the mode saturation voltage collector - emitter of the transistor 19 is reduced, lowering the voltage applied to Pogranichnaya value of Imax(Smin). Similarly, if the level or amplitude of the current flowing in the circuit electrode 8 having a smaller area at the input of the limiter current density impact 4 exceeds the maximum value of Imax(Smin), the voltage drop across the resistor 32 is applied to the base - emitter voltage of the second p-n-p transistor 31 opens and enters the mode saturation voltage collector - emitter of the transistor 31 is reduced, lowering the voltage applied to the base - emitter voltage of the first p-n-p transistor 29, closing the last so that the current flowing in its emitter, limited to the value of Imax(Smin).

For the electrode 9 having larger than that of the electrode 8, the area limitations of the current limiter current density impact 5 does not occur, because the voltage drop generated by the flow of current Imax(Sminthrough the parallel connected resistors 20-22 (resulting in the electrode current) or 32-34 (flowing from electrode current) is not sufficient for opening respectively of the transistors 19 or 31.

Thus, the proposed device for electrotherapy in all cases ensure the safety of the patient during the procedure, as with the errors of the medical staff when C is of atora of the amplitude level of the impact.

SOURCES USED

1. A brief introduction to electrotherapy. Phisiomed Elektromedizin, Schnaittach-Laipersdorf, Germany. First printed 1995; Reprinted 1997, 1999, 2000.

2. Apparatus for electrical muscle stimulation EMS-30-1 Stimulus 1”, passport 1979

3. Pacemaker universal ES-2, passport V/O “Medexport”.

4. Device low-frequency therapy “Amplipulse-5”, passport/About “Medexport”.

5. The electrostimulator according to A. C. the USSR SU # 1819632 A1, class a 61 n 1/36, D. I. Long and M. C. Lukyanov, publ. 07.06.93, bull. No. 21 - a prototype.

Claims

Device for electrotherapy containing electrodes and connected in series shaper signal exposure and level control of the driving amplitude, characterized in that it additionally connected in series limiters current density impact on the number of electrodes of the patient and multi-pin connectors of the connection electrodes connected between the control level of the driving amplitude and the electrodes, each electrode connected to the output of its limiter current density impact through the first contact of his multi-pin connector, the other contacts of the connector-side electrodes provided permiscuity current impact.



 

Same patents:
The invention relates to medicine, namely to physiotherapy, and is intended for the rehabilitation of patients in the treatment of fractures of the pelvis

Galvanic comb // 2240840
The invention relates to medicine, namely to prevention devices, and is intended to affect the scalp, stimulation and hair growth

The invention relates to veterinary therapy, namely the treatment of cats in posleoperazionny period

The invention relates to animal husbandry

Dental capsule // 2229860
The invention relates to medicine, specifically to dentistry, and can be used for the treatment of periodontal diseases and diseases of the mucous membranes of the oral cavity, in particular stomatitis
The invention relates to medicine and is intended for diagnostics of muscular
The invention relates to medicine and is intended to perform electrotherapy

The invention relates to medical and biological engineering and can be used to influence human processes, as well as for treatment of various diseases in non-traditional ways
The invention relates to medicine, in particular, neurology, and can be used to treat Parkinson's disease, atherosclerotic encephalopathy with intellectual disabilities and memory, functional pain syndromes face and mouth

The invention relates to medicine, namely to Pediatrics, and is intended for the treatment of bedwetting in children and adolescents

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine; infectious therapy.

SUBSTANCE: device for plasma-dynamic treatment of infected wounds and cavities has high voltage electric pulse oscillator provided with low-sized high voltage pulse electric-charge unit housed inside carrier dielectric case. The case has co-axial electrode system which has ring-shaped and rod electrodes separated by dielectric insulator. Co-axial electrode system is placed inside optical-transparent quartz member made in form of flask which has perforated semispherical working end. Co-axial system is disposed to have space relatively inner surface of carrier case of unit. Part of internal surface of the unit - at the area of semispherical working end of flask - is made of material which is able to reflect radiation of visible and UF range of spectrum. Removable outlet union, provided with branch pipe connected to union, is mounted onto working part of carrier case of unit. Branch pipe is connected with member having perforated semispherical working end at the opposite side. Opposite edge part of carrier case has support sealing bushing with inlet pipe which is connected with ozone generator conjugated with vessel for containing oxygen. Inlet pipe communicates with space to inner surface of carrier case of the unit and outer surface of flask.

EFFECT: improved efficiency of treatment; improved reliability of operation.

10 cl, 2 ex

FIELD: medical engineering.

SUBSTANCE: device has means for stimulating sensory organs (auditory and visual analyzers), thermo- and mechanoreceptors and transcutaneous electrostimulation in various combinations and sequences. Device has technical means providing sensory irritations. A set of light-emitting diodes comprising white, blue, green, red ones or their combinations are applied in particular for stimulating visual analyzer. Some of them are located on internal surfaces of sun-protection glasses and others arranged on periphery as radial divergent lines. To stimulate auditory analyzer, a set of micro speakers is used, one of which is mounted in the center of head phone and the others are concentrically arranged at least in two rows on periphery. To stimulate mechanoreceptors, a set of infrared light-emitting diodes is used, one of which is mounted in the center of thermode and the others are concentrically arranged at least in two rows on periphery. To carry out transcutaneous electrostimulation, electrodes with centrally arranged contact plate and electrically isolated contact plates concentrically arranged at least in two rows on periphery. Sensory irritation generators have independent communication channels having centrally and peripherally arranged stimulators. The generators are electrically connected to control unit connected to PC.

EFFECT: wide range of functional applications; enhanced effectiveness of human organism mental correction.

2 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves creating therapeutic circuit fixed on patient body, at least two working therapeutic electrodes, measuring and analyzing patient-dependent electrophysical parameters, charging capacitive storage and its later discharging to the working therapeutic electrodes controlled with control unit. Transmitting defibrillation impulse of given power in discharging is carried out in dosed manner first with the first portion W1 of given power dose with the second portion W2 being accumulated on inductive defibrillation power accumulator and then with the second portion W2 of given power dose. Ratio of the first portion W1 of given power dose to the second portion W2 of given power dose of defibrillation impulse is selected from the range of 0.01 to 150. Defibrillation impulse current intensity is selected only when emitting the first portion W1 of given power dose. Cardiodefibrillation impulse is built as bipolar Gurvich impulse. The given power quantity usable for charging the capacitive defibrillator storage is selected to be equal to a value from the range of 4-500 J, defibrillation impulse current intensity being selected from the range of 0.005 to 175 A and voltage equal to a value from 3 to 30000 V. Means has power supply source having unit for controlling charge level of the capacitive storage, unit for building defibrillation pulses, switchboards formed by controlled keys, at least two working therapeutic electrodes and diodes bypassing the controlled keys, resistive current transducer, analog-to-digital converter and control unit having required functional communications to the analog-to-digital converter and controlled keys. The resistive current transducer is in current feeding bus having minimum potential relative to measuring unit under operation having analog-to-digital converter in its structure.

EFFECT: enhanced effectiveness of usage; high safety of patient treatment procedure.

7 cl, 9 dwg

FIELD: medical engineering.

SUBSTANCE: device has n channels where n is even number. Each channel has stimulating signal generator and stimulating signal shaper. The stimulating signal generator has delay unit, unit for blanking coincident signals, packet envelope shaper and pulse packet oscillator. The stimulating signal shaper has power amplifier and unit containing the first starting cell and the first digital display. Unit for determining mean step is introduced into each stimulating signal generator. The unit output is connected to information inputs of delay unit and of stimulating signal shaper. The first input is combined with delay unit input and is called stimulating signal generator Start input. The second one is combined with corresponding delay unit input and packet envelope shaper and is called Set Zero input of the stimulating signal generator. Output of the unit for blanking coincident signals is connected to packet envelope shaper input. I-th stimulating signal generator delay unit output (I=1...n) is connected to i-th input of the unit for blanking coincident signals and serves as output of delayed signals. Inputs of the unit for blanking coincident signals (with the exception of the i-th one) form a group of delayed signals inputs of the stimulating signals generator. Information outputs of the delay unit and of the packet envelope shaper are the first and the second information outputs of the stimulating signal generator, respectively. Packet envelope shaper output is connected to packet envelope generator start input which output is signal output of the stimulating signal generator.

Packet envelope shaper output is processes visualization output of the stimulating signals generator. Each stimulating signal shaper additionally has in series connected attenuator and output transformer symmetric output of which is shaper signal output. Inverter has input connected to power amplifier output. Switch is available between outputs from the power amplifier, inverter and attenuator input. Power amplifier input serves as signal input of the shaper. the second digital display, clock pulse oscillator, the first switch are introduced into movement corrector. The first input of the first switch is connected to clock pulse oscillator output, the output being connected to combined Start inputs of stimulating signals generators having visualization input with its signal inputs being connected to stimulating signals generators processes visualization outputs. The second switch has output connected to synchronizing output of visualization unit input. The third switch has the first and the second outputs connected to the second and the third inputs of the first switch, respectively. Three start transducers make start transducers set with the available one with the first, the second, the third and the fourth outputs are connected to the second and the third switch inputs. The fourth and the fifth switch are available between the first and the second information outputs of stimulating signals generators, respectively. Output of the delayed signals of i-th stimulating signals generator (I=1...n) is connected to inputs of delayed signals group from the remaining stimulating signals generators. Set Zero inputs of the stimulating signals generators are joined together forming movement corrector Set Zero input.

EFFECT: wide range of functional applications; enhanced effectiveness in treating patient possessing heavy locomotor apparatus disorders both in rest state and in moving.

4 cl, 5 dwg

FIELD: medicine, ophthalmology.

SUBSTANCE: the present innovation deals with treating different forms of amblyopia. It is necessary to carry out medicinal correction of neurological disorders in a patient that includes vasoactive preparations, venotonics, nootropes and metabolics. One should conduct electrophoresis of spasmolytics onto area of jugular vertebral department at current power being 0.5-1.0 mA/sq. cm per 10 min, daily. Simultaneously,, it is necessary to carry out argon-laser stimulation of retinal central area and projection of papillo-macular bundle, about 150-200 impulses/seance, radiation power being 0.05 W, radiation diameter of 1000 mc, exposure time of 0.01 sec, wave length being 498-514 nm every other day. Therapy course lasts for 10 d. The innovation enables to achieve positive dynamics in treating severe forms of amblyopia, restore visual function and obtain correction of neurological disorders.

EFFECT: higher efficiency of therapy.

4 ex

FIELD: medical equipment, applicable for treatment of various inflammatory diseases.

SUBSTANCE: the device has a noise current generator, catheter, series-connected personal computer, control unit and a filter unit, whose input is connected to the output of the noise current generator, the output is connected to the catheter, and the personal computer is provided with a dialogue software of experiment planning.

EFFECT: provided approximation of the frequency spectrum of the current acting on the man organs and tissues to the therapeutically optimal value by determination of the optimal combination of the tuning frequencies and the quantity of filters by the methods of mathematical planning of experiment with employment of a personal computer.

1 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing photosensitizer in pharmaceutical water-soluble dosage form at a dose of 1.5-2.0 mg/kg * 0.7 during 40-60 min. Blood is concurrently exposed to laser radiation at a dose of 600-900 J/cm3. The wavelength is selected to match photosensitizer absorption maximum in the water-soluble dosage form. Chlorine row photosensitizer is introduced 3-3.5h later in liposome form at a dose of 1.5-2.0 mg/kg*0.3. 15 min later, laser radiation is applied all over the whole tumor perimeter in transpupillary mode with neighboring fields overlap by 5% of area with power density of 80-100 J/cm2. The wavelength is selected to match photosensitizer absorption maximum in the liposome form. Then the whole neoplasm surface is irradiated in transpupillary mode in laser radiation fields in circle moving from periphery to the center with neighboring fields overlap being equal to 5% of area. The wavelength is selected to match photosensitizer absorption maximum in the water-soluble dosage form. Power density of 80-100 J/cm2 in peripheral part is gradually increased when moving towards the center to 100-120 J/cm2. Two weeks later, localization is adjusted in diaphanoscopic transscleral way and electrochemical destruction of intraocular neoplasm is carried out with current intensity of 10-100 mA during 10-1 min.

EFFECT: enhanced effectiveness in achieving complete or partial tumor regress; reduced risk of metastatic complications.

4 cl

Up!